Tolerability and Efficacy of Naratriptan Tablets in the Acute Treatment of Migraine Attacks for 1 Year

Heywood, J; Bomhof, M.A.M.; Pradalier, A; Thaventhiran, L; Winter, P D; Hassani, Habib

doi:10.1046/j.1468-2982.2000.00066.x

Cited by 20 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Naratriptan also had tolerability similar to placebo in 2 similarly designed double‐blind, parallel‐group studies in which patients took naratriptan 1 mg twice daily for 6 days beginning 3 days before the expected onset of MRM during up to 4 menstrual cycles or for a 6‐month period, whichever occurred first 11,12 . The tolerability profile of naratriptan appears similar to placebo when used for short‐term prevention of MRM and is consistent with the tolerability profile observed in acute migraine studies 13–15 …”

Section: Commentssupporting

confidence: 69%

“…Similarly, the tolerability profile of naratriptan 2.5 mg was comparable to that of placebo in controlled studies in which the drug was given as acute treatment for single migraine attacks 13,14 . Furthermore, in an open‐label study in which 417 patients administered naratriptan 2.5 mg for the acute treatment of 15,301 migraine attacks, the only adverse event reported in more than 2% of attacks was nausea (3%), a symptom of migraine 15 . While these data suggest that naratriptan is sufficiently well tolerated for intermittent use as prophylaxis, the tolerability of naratriptan administered intermittently for prophylaxis for MRM over the long term has not been assessed to date.…”

mentioning

confidence: 83%

See 1 more Smart Citation

Open‐Label, Long‐Term Tolerability of Naratriptan for Short‐Term Prevention of Menstrually Related Migraine

Brandes¹,

Smith²,

Ames³

2007

Headache

View full text Add to dashboard Cite

show abstract

Section: Commentssupporting

confidence: 69%

mentioning

confidence: 83%

Open‐Label, Long‐Term Tolerability of Naratriptan for Short‐Term Prevention of Menstrually Related Migraine

Brandes¹,

Smith²,

Ames³

2007

Headache

View full text Add to dashboard Cite

show abstract

“…44 Treated patients had headache relief in a median of 70% of moderate or severe and 86% of mild attacks, 4 hours after dosing. Furthermore, headache relief remained the same over prolonged treatment (0-6 versus 6-12 months) and frequency of naratriptan use (up to or over 36 attacks).…”

Section: Naratriptanmentioning

confidence: 99%

“…AEs were absent in 84% of treated attacks and did not increase with respect to the number of doses. 44 A comparative randomised, double-blind, crossover study comparing naratriptan with sumatriptan in 253 migraine patients (safety analysis) with a history of frequent headache recurrence has been reported. 45 The efficacy analysis included 225 patients who treated two attacks.…”

Section: Naratriptanmentioning

confidence: 99%

Overview of Triptans in the Treatment of Acute Migraine

Cortelli¹,

Allais²,

Benedetto³

2017

European Neurological Review

View full text Add to dashboard Cite

T he advent of triptans for effective relief of migraine represented a therapeutic breakthrough. Triptans are serotonin (5-hydroxytryptamine, or 5-HT) agonists with high affinity for 5-HT 1B and 5-HT 1D receptors. There are, at present, seven commonly used triptans: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. Some controversy still surrounds the mode of action of this class. When first studied, it was thought that triptans provided relief from migraine through cranial vasoconstriction, probably via action at postsynaptic 5-HT 1B receptors on the smooth-muscle cells of blood vessels. More recently, however, triptans have also been demonstrated to block release of vasoactive peptides from the perivascular trigeminal neurons owing to their action at presynaptic 5-HT 1D receptors on the nerve terminal. Triptans may also facilitate descending pain inhibitory systems. However, it is not certain whether or not the activation of vascular 5-HT 1B receptors is essential for relieving migraine. Many drug characteristics need to be taken into account when selecting the best triptan for an individual patient. Clinical characteristics of the migraine attack and the patient's lifestyle and medical history are also important. Despite their biochemical similarity, triptans have distinct pharmacokinetic and pharmacodynamic profiles. Frovatriptan and naratriptan, for example, have a longer half-life and therefore a delayed onset of action and prolonged duration compared with the other triptans, which are fast acting, with a rapid dose-dependent efficacy and higher risk of adverse events and migraine recurrence. Migraine recurrence is affected by the pharmacological and pharmacokinetic properties of the triptan but is unrelated to initial clinical efficacy. Triptans with a longer half-life and largest 5-HT 1B receptor affinity have the lowest rates of headache recurrence.

show abstract

“…These data support the efficacy of naratriptan in the acute treatment of migraine 4 h after treatment, but efficacy at early time points (within 2 h following treatment) has not been established. At an oral dose of 2.5 mg, nara triptan has a favorable side-effect profile and is undistinguishable from placebo [54].…”

Section: Naratriptanmentioning

confidence: 99%

The triptans

Bigal¹,

Krymchantowski²,

Hargreaves³

2009

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

The migraine-specific triptans have revolutionized the treatment of migraine and are currently the drugs of choice to treat a migraine attack in progress. Over the past 15 years, triptans were released in rapid succession, with each one demonstrating some specific pharmacokinetic properties that may be translated into clinical advantages. Triptans share many similarities, but also have important differences from one another. Accordingly, herein we discuss the class of the triptans. We first define the trigeminovascular system and its importance in migraine pain, then discuss the mechanism of action of the triptans and contrast the evidence supporting the use of different triptans. We close with our view of the future and hopes for the next generation of antimigraine therapies.

show abstract

Tolerability and Efficacy of Naratriptan Tablets in the Acute Treatment of Migraine Attacks for 1 Year

Abstract: The results of this study demonstrate that naratriptan tablets 2.5 mg taken for acute migraine attacks over a 1-year period are well-tolerated and effective.

Cited by 20 publications

References 8 publications

Open‐Label, Long‐Term Tolerability of Naratriptan for Short‐Term Prevention of Menstrually Related Migraine

Open‐Label, Long‐Term Tolerability of Naratriptan for Short‐Term Prevention of Menstrually Related Migraine

Overview of Triptans in the Treatment of Acute Migraine

The triptans

Contact Info

Product

Resources

About